Bioprojet UK

What Bioprojet UK does

Bioprojet UK Limited is a UK-based pharmaceutical company that supplies and commercialises prescription medicines developed by its parent, Bioprojet Pharma, across the United Kingdom and Ireland. The company began operations as Lincoln Medical in 2000, was acquired by Paris-headquartered Bioprojet Pharma in 2014, and was formally rebranded as Bioprojet UK Limited in 2021. It operates from a small commercial office in Salisbury, Wiltshire, with 1-10 employees, and functions as the regional commercial arm of the parent group rather than as an independent R&D entity.

The company's product portfolio targets three therapeutic areas with significant unmet medical needs: sleep disorders (narcolepsy, obstructive sleep apnoea-hypopnoea syndrome, and excessive daytime sleepiness), allergy and immunology (anaphylaxis and severe allergic reactions), and gastroenterology. Products are developed and manufactured by parent Bioprojet Pharma, a pharmaceutical laboratory with over 30 years of drug development experience. The UK/Ireland entity handles local commercialisation, distribution through licensed pharmaceutical wholesalers and direct-to-institution channels, healthcare professional outreach, patient advocacy engagement (including with Narcolepsy UK), and pharmacovigilance reporting via MHRA (UK) and HPRA (Ireland) channels.

The business model is prescription pharmaceutical sales with NHS/healthcare-system-determined pricing. Revenue is generated from the sale of proprietary, prescription-only medicines to fragmented prescriber and patient populations across UK and Ireland. Non-core medical information handling is outsourced to Jenson Group, while pharmacovigilance, regulatory compliance, and commercial operations remain in-house. Pricing is not publicly disclosed, and the entity is entirely funded and controlled by parent Bioprojet Pharma, with no external funding rounds.

Name

Bioprojet UK

Legal name

Bioprojet UK Limited

Website

https://bioprojet.uk

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

1–10 employees

Short description

Bioprojet UK Limited is a wholly-owned UK subsidiary of French pharmaceutical laboratory Bioprojet Pharma, commercialising prescription medicines for sleep disorders, gastroenterology, and allergy/immunology across the United Kingdom and Ireland.

Ownership category

akta.pro rank

Product category

Prescription Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro industry

PRIMARYHLAIACAF

Pulmonology & Allergy Specialty Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Specialty Pharmaceuticals

SECONDARYHLAIACAC

Neurology & CNS Specialty Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Specialty Pharmaceuticals

SECONDARYHLAIAAAH

Respiratory & Allergy Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

• Prescription pharmaceuticals
• Sleep disorder treatments
• Narcolepsy therapy
• Allergy immunology drugs
• Gastroenterology medicines

Headquarters

HQ city

Salisbury

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pharmaceutical product sales: Bioprojet UK supplies and commercialises Bioprojet pharmaceutical products across the United Kingdom and Ireland. As a pharmaceutical company, revenue is generated through the sale of prescription medicines targeting sleep disorders (narcolepsy, excessive daytime sleepiness), gastroenterology conditions, and allergy & immunology disorders including anaphylaxis.

Distribution channels1 record

Marketing channels3 records

Core offering

Bioprojet UK Limited supplies and commercialises prescription-only pharmaceutical products developed by its parent company Bioprojet Pharma across the United Kingdom and Ireland. The portfolio targets three core therapeutic areas: sleep disorders (narcolepsy, obstructive sleep apnoea-hypopnoea syndrome, excessive daytime sleepiness), allergy and immunology (anaphylaxis), and gastroenterology. Products are distributed through licensed pharmaceutical wholesalers and supplied to healthcare professionals for the treatment of patients with significant unmet medical needs.

Product overview

Bioprojet UK is a pharmaceutical company that commercialises medicines across the United Kingdom and Ireland. The company operates as part of the Bioprojet Pharma group (headquartered in Paris, France) and focuses on three core therapeutic areas: sleep disorders (including narcolepsy and obstructive sleep apnoea), gastroenterology, and allergy & immunology (particularly anaphylaxis). The product portfolio consists of prescription pharmaceutical products designed to address significant unmet medical needs in these therapeutic areas, with an emphasis on improving patient quality of life. The products are developed by the parent company Bioprojet Pharma, which has over 30 years of experience designing and developing medicines.

Differentiator

Problem solved

Functional benefit

Products and services

• Narcolepsy Treatment
• Obstructive Sleep Apnoea-Hypopnoea Syndrome (OSAHS) Treatment
• Anaphylaxis / Emergency Allergy Treatment
• Gastroenterology Treatments

Quantifiable outcome

• Narcolepsy affects 1 person in 2500 in the UK, representing approximately 30,000 patients

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Bioprojet PharmacoreStrategic or Co-development Partner · 1 January 2014Bioprojet Pharma, headquartered in Paris, France, acquired Lincoln Medical (now Bioprojet UK Limited) in 2014. Bioprojet Pharma is a pharmaceutical laboratory founded over 30 years ago committed to innovation in the service of health. The parent company designs and develops medicines with patient needs at the core of their approach.

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Harmony Biosciences: US specialty pharma commercialising Wakix (pitolisant), a direct therapeutic competitor in narcolepsy with cataplexy, sharing Bioprojet's focus on CNS sleep-wake disorders.
• Jazz Pharmaceuticals: Global specialty pharma with leading narcolepsy franchises (Xyrem/Xywav/Epidiolex) directly competing in the same CNS sleep-disorder prescribing base that Bioprojet UK targets.
• Avadel Pharmaceuticals: Specialty pharma focused on narcolepsy (Lumryz/sodium oxybate), competing head-to-head with Bioprojet's narcolepsy franchise in sleep disorder specialists.

Regional players

• Norgine: UK and European-headquartered specialty pharma with strong gastroenterology and hospital-prescription portfolio, comparable in scale and commercial orientation to Bioprojet UK in the gastro therapy area.

Broad incumbents

• Takeda Pharmaceutical Company: Large pharmaceutical company with established sleep and respiratory franchises, including narcolepsy and rare disease therapies, overlapping with Bioprojet UK's CNS/respiratory focus.
• ALK-Abelló: Global allergy immunotherapy leader with allergy and anaphylaxis-adjacent products; broad incumbent rather than direct competitor but addresses overlapping prescribers and patient populations.
• Kyowa Kirin: Global specialty pharma with neurology and rare disease franchises, including products in sleep-wake disorders, competing indirectly for the same CNS prescriber base.
• Stallergenes Greer: Specialty allergy company focused on allergen immunotherapy and anaphylaxis-related products; broader player than Bioprojet UK but operates in shared allergy and immunology channels.

Emerging players

• Veriton Pharma: UK-based specialty pharma commercialising niche prescription products through targeted sales and medical channels; comparable in scale, structure, and asset-light commercial model to Bioprojet UK.

Others

• Bioprojet Pharma: Paris-based parent pharmaceutical laboratory that develops and supplies the products Bioprojet UK commercialises; a corporate parent rather than commercial peer but the source of the underlying portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/bioprojet-uk-limited

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bioprojet UK